2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow Xevinapant: new trials by email Literature Review of Xevinapant trials Research Report on Xevinapant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer Xevinapant, Placebo, cetuximab - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Terminated | Groupe Oncologie Radiotherapie Tete et Cou | 19 | 2023-12-12 | 2025-05-09 |
| Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) Xevinapant, IMRT, Placebo - Head and Neck Cancer | Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 166 | 2022-10-06 | 2026-02-19 |
Head and Neck Neoplasms (1) · Laryngeal Diseases (1) · Squamous Cell Carcinoma of Head and Neck (1)
EMD Serono Research & Development Institute, Inc. (1) · Groupe Oncologie Radiotherapie Tete et Cou (1)
France (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Czechia (1) · Georgia (1) · Germany (1) · Greece (1) · India (1) · Israel (1) · Italy (1) · Japan (1)
2023 (1)